GPS Wealth Strategies Group’s CRISPR Therapeutics CRSP Stock Holding History

GPS Wealth Strategies Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$7.97K	Sell	152 -337	-69%	-$20.2K	0.01%	417
2025 Q3	$31.7K	Sell	489 -26	-5%	-$1.49K	﹤0.01%	780
2025 Q2	$25.1K	Hold	515	–	–	﹤0.01%	807
2025 Q1	$17.5K	Buy	515 +25	+5%	+$1.06K	﹤0.01%	857
2024 Q4	$19.3K	Sell	490 -127	-21%	-$6K	﹤0.01%	804
2024 Q3	$29K	Buy	617 +2	+0.3%	+$101	﹤0.01%	711
2024 Q2	$33.2K	Buy	615 +307	+100%	+$17.8K	0.01%	642
2024 Q1	$21K	Sell	308 -15	-5%	-$1.07K	﹤0.01%	712
2023 Q4	$20.2K	Buy	323 +100	+45%	+$5.53K	﹤0.01%	695
2023 Q3	$10.1K	Buy	223 +15	+7%	+$775	﹤0.01%	836
2023 Q2	$11.7K	Buy	208 +183	+732%	+$10.4K	﹤0.01%	821
2023 Q1	$1.13K	Buy	+25	New	+$1.21K	﹤0.01%	1155
2022 Q4	–	Sell	-25	Closed	-$2K	–	323
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1028
2022 Q2	$2K	Hold	25	–	–	﹤0.01%	1010
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	959
2021 Q4	$2K	Hold	25	–	–	﹤0.01%	975
2021 Q3	$3K	Buy	+25	New	+$3.14K	﹤0.01%	899

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GPS Wealth Strategies Group's CRSP Position: Q4 2025 in Review

GPS Wealth Strategies Group reduced its CRISPR Therapeutics (CRSP) stake by 69% in Q4 2025, selling an estimated $20.2K and leaving 152 shares worth $7.97K. The position accounts for 0.01% of the portfolio, ranked #417.

GPS Wealth Strategies Group first reported a position in CRSP in Q3 2021 and has held it in 17 quarters since. The position peaked at $33.2K in Q2 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

GPS Wealth Strategies Group held 152 shares of CRISPR Therapeutics worth $7.97K as of Q4 2025.
GPS Wealth Strategies Group sold 337 CRISPR Therapeutics shares in Q4 2025, an estimated $20.2K.
CRISPR Therapeutics made up 0.01% of GPS Wealth Strategies Group's portfolio in Q4 2025, its #417 holding.
GPS Wealth Strategies Group first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 17 quarters since.
GPS Wealth Strategies Group's CRISPR Therapeutics position peaked at $33.2K in Q2 2024.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2025, filed 6 Feb 2026.